** Drugmaker Biogen's shares BIIB.O fall 1.32% to $137.55 premarket
** Co forecasts 2025 adj. profit between $15.25/shr and $16.25/shr, below analyst est. of $16.34/shr, according to data compiled by LSEG
** Co reports Q4 profit of $3.44/shr, higher than analyst est. of $3.35/shr
** BIIB said it expects revenue to decline by a mid-single digit percentage in 2025 compared to 2024
** Co posts 2024 rev. of $9.68 bln, down 2% from a year earlier
** Stock fell ~42% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.